Personalized 5-FU dosing for advanced gastrointestinal cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether doctors can safely find the best dose of 5-FU, a chemotherapy medicine, for people with advanced gastrointestinal cancers. The goal is to reduce side effects while still treating the cancer effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have advanced or spreading gastrointestinal cancer (including colon/rectum or cancers of the stomach, esophagus, appendix, small bowel, or ampulla)
- You can have scans of the chest, abdomen, and pelvis within the last 30 days
- Your overall activity level is good (ECOG 0–1, meaning you can do most daily activities)
- You have not had certain prior chemotherapy: oxaliplatin or fluoropyrimidine chemotherapy (5-FU–type) besides special “radiation-sensitizing” use, and no systemic chemo in the last 6 months
- You do not have specific genetic or safety risks (no mismatch repair deficiency/MSI-high, no DPD deficiency), and your blood tests and organ tests are high enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adjusting the dose of chemotherapy drugs (5-FU or capecitabine plus oxaliplatin) based on a liver enzyme test can improve safety and effectiveness for people with gastrointestinal cancer who are starting this type of chemo for the first time.
This trial tests putting a chemo drug (fluorouracil) directly into the colon through a tube. It's for people with colorectal cancer who are already getting other cancer treatment, to see if adding local chemo helps shrink the main tumor.
This trial tests a modified version of a common chemotherapy combination (capecitabine and oxaliplatin) for people with gastrointestinal cancers who are not expected to be cured. It aims to see if a simpler treatment schedule can be just as effective while reducing side effects.
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
This trial tests a combination of three chemotherapy drugs plus a targeted therapy as a first treatment for advanced colorectal cancer. The goal is to see if this strong drug mix can shrink tumors better than standard approaches.
This trial tests two different chemotherapy regimens (FOLFOX8 and mFOLFOX6), each paired with a targeted drug (bevacizumab or cetuximab), to treat colorectal cancer that has spread and cannot be surgically removed. The goal is to find which combination works best as a first treatment.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.